Literature DB >> 18663294

Optimizing otoacoustic emission protocols for a UNHS program.

S Hatzopoulos1, J Petruccelli, A Ciorba, A Martini.   

Abstract

OBJECTIVE: To identify the optimal test protocol to screen for hearing problems in newborns, an evaluation of three distortion product otoacoustic emission (DPOAE) protocols was conducted in neonates, from a well-baby nursery (WBN) and from a neonatal intensive care unit (NICU) and compared to the performance in newborns of a more standard protocol based on transient-evoked OAEs (TEOAEs).
METHODS: The DPOAE protocols used asymmetrical stimulus intensities (L(1) > L(2)) with a frequency ratio of 1.22, in the following format: (P1), L(1) = 60, L(2) = 50 dB SPL; (P2), L(1) = 65, L(2) = 55 dB SPL, and (P3), L(1) = 75, L(2) = 65 dB SPL. Linear TEOAE responses, evoked by click stimuli of 75 dB peSPL, were used as controls of normal cochlear function. Five frequencies at 1.5, 2.0, 3.0, 4.0 and 5.0 kHz were tested with a common commercially available macro-based software subroutine (Otodynamics Corp, ILO-92). The project evaluated the responses from 1200 WBN infants (average age 48 h) and 350 low-birth-weight NICU infants, all randomly selected.
RESULTS: Statistical analyses comparing the signal-to-noise ratios (S/N), at the predefined f(2) frequencies, indicated that the P1 and P2 DPOAE protocols generated similar responses. Significant S/N differences were observed in the P3 to P2 dataset comparisons. DPOAE scoring criteria were estimated from the P3 dataset using a one-sided, distribution-free confidence intervals. The scoring criteria for a 'pass' were estimated as a minimum S/N of 6.0, 7.0 and 6.0 dB at 2.0, 3.0 and 4.0 kHz, respectively. In terms of feasibility, the P3 protocol generated responses in 98% of the WBN and 94.8% of the NICU infants.
CONCLUSIONS: All three DPOAE protocols demonstrated shorter time-recording requirements than the standard TEOAE test. The false-positive and false-negative rates for the NICU infants were estimated as 0.0028 and 0.003%, respectively.

Entities:  

Mesh:

Year:  2008        PMID: 18663294     DOI: 10.1159/000148205

Source DB:  PubMed          Journal:  Audiol Neurootol        ISSN: 1420-3030            Impact factor:   1.854


  6 in total

1.  Evaluation of an automated auditory brainstem response in a multi-stage infant hearing screening.

Authors:  Luca Guastini; Renzo Mora; Massimo Dellepiane; Valentina Santomauro; Massimiliano Mora; Antonio Rocca; Angelo Salami
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-02-11       Impact factor: 2.503

Review 2.  Universal newborn hearing screening, a revolutionary diagnosis of deafness: real benefits and limitations.

Authors:  George X Papacharalampous; Thomas P Nikolopoulos; Dimitrios I Davilis; Ioannis E Xenellis; Stavros G Korres
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-06-23       Impact factor: 2.503

3.  Effect of sepsis and systemic inflammatory response syndrome on neonatal hearing screening outcomes following gentamicin exposure.

Authors:  Campbell P Cross; Selena Liao; Zachary D Urdang; Priya Srikanth; Angela C Garinis; Peter S Steyger
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2015-09-09       Impact factor: 1.675

4.  Contralateral suppression of otoacoustic emissions: input-output functions in neonates.

Authors:  Ualace de Paula Campos; Stavros Hatzopoulos; Krzysztof Kochanek; Lech Sliwa; Henryk Skarzynski; Renata Mota Mamede Carvallo
Journal:  Med Sci Monit       Date:  2011-10

5.  Identifying congenital hearing impairment: preliminary results from a comparative study using objective and subjective audiometric protocols.

Authors:  A Ciorba; S Hatzopoulos; J Petruccelli; M Mazzoli; A Pastore; K Kochanek; P Skarzynski; A Wlodarczyk; H Skarzynski
Journal:  Acta Otorhinolaryngol Ital       Date:  2013-02       Impact factor: 2.124

6.  Contralateral ear occlusion for improving the reliability of otoacoustic emission screening tests.

Authors:  Emily Papsin; Adrienne L Harrison; Mattia Carraro; Robert V Harrison
Journal:  Int J Otolaryngol       Date:  2014-01-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.